The Inventurus Knowledge Solutions (IKS Health) IPO has opened for public subscription, generating significant market buzz. With a total issue size of ₹2,498 crore and a price band set between ₹1,265 and ₹1,329, the IPO has drawn interest from anchor investors and retail participants alike. Here’s a detailed analysis of the IPO, its grey market premium (GMP), valuation, and whether you should consider subscribing.
Key Details of the IKS Health IPO
| Particulars | Details |
|---|---|
| Issue Size | ₹2,498 crore |
| Offer Type | 100% Offer for Sale (OFS) |
| Price Band | ₹1,265 – ₹1,329 |
| Grey Market Premium (GMP) | ₹422 (31.75% above upper price band) |
| Employee Reservation | 65,000 shares |
| Anchor Investors Raised | ₹1,120.18 crore |
| Market Cap at Upper Band | ₹22,802 crore |
| PE Ratio | 54.66x (Fully diluted post-IPO) |
Financials and Growth Trajectory
Inventurus Knowledge Solutions has shown consistent financial growth over the years, supported by its integrated healthcare solutions and a robust client base. However, the IPO comes at a time when Ebitda margins have seen a temporary dip due to acquisition integration.
- Strengths:
- Long-standing relationships with over 778 healthcare organizations.
- Diversified client portfolio, including Mass General Brigham Inc., Texas Health Care PLLC, and The GI Alliance Management.
- Leading position in outpatient and inpatient care solutions.
- Concerns:
- The IPO is entirely an Offer for Sale (OFS), meaning no proceeds will go to the company.
- PE valuation of 54.66x is considered fully priced by analysts, limiting short-term upside potential.
Analysts’ Views
Rajan Shinde, Mehta Equities
- Recommendation: Subscribe for long-term investment.
- Insight: While Ebitda margins are expected to improve, the fully priced valuation and 100% OFS nature of the issue may deter short-term investors.
Swastika Investmart
- Recommendation: Suitable for long-term investors.
- Insight: Highlights the company’s strong financial track record and lack of listed peers, making it a premium offering.
Grey Market Premium (GMP)
The grey market premium (GMP) for IKS Health is ₹422, translating to a 31.75% premium over the upper price band of ₹1,329. This indicates strong demand in the grey market and positive sentiment among investors.
Key Highlights of Anchor Investors
Ahead of the IPO, Inventurus Knowledge Solutions raised ₹1,120.18 crore from 61 anchor investors, including:
- Fidelity Funds
- Abu Dhabi Investment Authority
- Prudential Hong Kong
- HSBC Global
- Government Pension Fund Global
33.33% of the allocation to anchor investors was made to 12 domestic mutual funds through 23 schemes.
Should You Subscribe?
Pros:
- Strong client relationships across healthcare organizations.
- Leadership in integrated healthcare solutions.
- Robust GMP and positive anchor investor participation.
Cons:
- Fully priced valuation at 54.66x PE.
- No proceeds from the IPO will go to the company due to its OFS nature.
Verdict:
If you are a long-term investor, subscribing to the IKS Health IPO may be a worthwhile consideration, given the company’s financial strength and growth potential. Short-term investors should remain cautious due to the high valuation and limited upside in the near term.
Click here to know more.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor before making investment decisions.